A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy
- Author
- SHIRAKAWA, Tsuyoshi1 2 ; KATO, Ken1 ; TAKASHIMA, Atsuo1 ; OKITA, Natsuko1 ; HAMAGUCHI, Tetsuya1 ; YAMADA, Yasuhide1 ; SHIMADA, Yasuhiro1 ; NAGASHIMA, Kengo3 ; NISHIKAWA, Akiko1 ; SAWADA, Ryoichi1 ; TAKAHASHI, Naoki1 ; SHOJI, Hirokazu1 ; SASAKI, Yusuke1 ; HONMA, Yoshitaka1 ; IWASA, Satoru1
[1] Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
[2] Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka-shi 811-1395, Japan
[3] Clinical Research Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan - Source
Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 6, pp 1207-1215, 9 p ; ref : 24 ref
- CODEN
- CCPHDZ
- ISSN
- 0344-5704
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Springer, Heidelberg
- Publication country
- Germany
- Document type
- Article
- Language
- English
- Author keyword
- Docetaxel Esophageal squamous cell carcinoma Paclitaxel Prognostic factor Second-line chemotherapy
- Keyword (fr)
- Anticancéreux Cancer de l'oesophage Carcinome épidermoïde de l'oesophage Chimiothérapie Docétaxel Dérivé de la fluoropyrimidine Homme Paclitaxel Pronostic Récidive Rétrospective Stade avancé Toxicité Traitement de deuxième intention Platine II Complexe Antimitotique Cancer Dérivé du taxane Pathologie de l'appareil digestif Pathologie de l'oesophage Traitement Tumeur maligne
- Keyword (en)
- Antineoplastic agent Esophagus cancer Esophagus squamous cell carcinoma Chemotherapy Docetaxel Fluoropyrimidine derivatives Human Paclitaxel Prognosis Relapse Retrospective Advanced stage Toxicity Second line treatment Antimitotic Cancer Taxane derivatives Digestive diseases Esophageal disease Treatment Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del esófago Carcinoma epidermoide de esófago Quimioterapia Docetaxel Fluoropirimidina derivado Hombre Paclitaxel Pronóstico Recaida Retrospectiva Estadio avanzado Toxicidad Tratamiento de segunda línea Antimitótico Cáncer Taxane derivado Aparato digestivo patología Esófago patología Tratamiento Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R01 General aspects
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13A Esophagus / 002B13A01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 28934766
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s00280-014-2597-3 
https://dx.doi.org/10.1007/s00280-014-2597-3
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-014-2597-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:196:\"A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1207\";s:8:\"\u0000*\u0000epage\";s:4:\"1215\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SHIRAKAWA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Tsuyoshi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:9:\"KATO, Ken\";i:1;s:16:\"TAKASHIMA, Atsuo\";i:2;s:14:\"OKITA, Natsuko\";i:3;s:18:\"HAMAGUCHI, Tetsuya\";i:4;s:16:\"YAMADA, Yasuhide\";i:5;s:17:\"SHIMADA, Yasuhiro\";i:6;s:16:\"NAGASHIMA, Kengo\";i:7;s:16:\"NISHIKAWA, Akiko\";i:8;s:15:\"SAWADA, Ryoichi\";i:9;s:16:\"TAKAHASHI, Naoki\";i:10;s:15:\"SHOJI, Hirokazu\";i:11;s:14:\"SASAKI, Yusuke\";i:12;s:16:\"HONMA, Yoshitaka\";i:13;s:13:\"IWASA, Satoru\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:196:\"A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-014-2597-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:196:\"A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1207\";s:8:\"\u0000*\u0000epage\";s:4:\"1215\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SHIRAKAWA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Tsuyoshi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:9:\"KATO, Ken\";i:1;s:16:\"TAKASHIMA, Atsuo\";i:2;s:14:\"OKITA, Natsuko\";i:3;s:18:\"HAMAGUCHI, Tetsuya\";i:4;s:16:\"YAMADA, Yasuhide\";i:5;s:17:\"SHIMADA, Yasuhiro\";i:6;s:16:\"NAGASHIMA, Kengo\";i:7;s:16:\"NISHIKAWA, Akiko\";i:8;s:15:\"SAWADA, Ryoichi\";i:9;s:16:\"TAKAHASHI, Naoki\";i:10;s:15:\"SHOJI, Hirokazu\";i:11;s:14:\"SASAKI, Yusuke\";i:12;s:16:\"HONMA, Yoshitaka\";i:13;s:13:\"IWASA, Satoru\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:196:\"A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-014-2597-3\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-014-2597-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:196:\"A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1207\";s:8:\"\u0000*\u0000epage\";s:4:\"1215\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SHIRAKAWA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Tsuyoshi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:9:\"KATO, Ken\";i:1;s:16:\"TAKASHIMA, Atsuo\";i:2;s:14:\"OKITA, Natsuko\";i:3;s:18:\"HAMAGUCHI, Tetsuya\";i:4;s:16:\"YAMADA, Yasuhide\";i:5;s:17:\"SHIMADA, Yasuhiro\";i:6;s:16:\"NAGASHIMA, Kengo\";i:7;s:16:\"NISHIKAWA, Akiko\";i:8;s:15:\"SAWADA, Ryoichi\";i:9;s:16:\"TAKAHASHI, Naoki\";i:10;s:15:\"SHOJI, Hirokazu\";i:11;s:14:\"SASAKI, Yusuke\";i:12;s:16:\"HONMA, Yoshitaka\";i:13;s:13:\"IWASA, Satoru\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:196:\"A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-014-2597-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:196:\"A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1207\";s:8:\"\u0000*\u0000epage\";s:4:\"1215\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SHIRAKAWA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Tsuyoshi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:9:\"KATO, Ken\";i:1;s:16:\"TAKASHIMA, Atsuo\";i:2;s:14:\"OKITA, Natsuko\";i:3;s:18:\"HAMAGUCHI, Tetsuya\";i:4;s:16:\"YAMADA, Yasuhide\";i:5;s:17:\"SHIMADA, Yasuhiro\";i:6;s:16:\"NAGASHIMA, Kengo\";i:7;s:16:\"NISHIKAWA, Akiko\";i:8;s:15:\"SAWADA, Ryoichi\";i:9;s:16:\"TAKAHASHI, Naoki\";i:10;s:15:\"SHOJI, Hirokazu\";i:11;s:14:\"SASAKI, Yusuke\";i:12;s:16:\"HONMA, Yoshitaka\";i:13;s:13:\"IWASA, Satoru\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:196:\"A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-014-2597-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:196:\"A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1207\";s:8:\"\u0000*\u0000epage\";s:4:\"1215\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SHIRAKAWA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Tsuyoshi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:9:\"KATO, Ken\";i:1;s:16:\"TAKASHIMA, Atsuo\";i:2;s:14:\"OKITA, Natsuko\";i:3;s:18:\"HAMAGUCHI, Tetsuya\";i:4;s:16:\"YAMADA, Yasuhide\";i:5;s:17:\"SHIMADA, Yasuhiro\";i:6;s:16:\"NAGASHIMA, Kengo\";i:7;s:16:\"NISHIKAWA, Akiko\";i:8;s:15:\"SAWADA, Ryoichi\";i:9;s:16:\"TAKAHASHI, Naoki\";i:10;s:15:\"SHOJI, Hirokazu\";i:11;s:14:\"SASAKI, Yusuke\";i:12;s:16:\"HONMA, Yoshitaka\";i:13;s:13:\"IWASA, Satoru\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:196:\"A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
